A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants

NCT ID: NCT02475148

Last Updated: 2025-02-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 76 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2015-10-31

Brief Summary

The purpose of this study is to investigate the safety and tolerability of JNJ-54175446 versus placebo after single oral dose administration (ascending dose levels), to determine the maximal tolerated dose (MTD) or the safety and tolerability at exposures resulting in full target engagement for at least 24 hours in all participants (whichever comes first), to characterize the pharmacokinetics of JNJ-54175446 in plasma, cerebrospinal fluid (CSF) and urine and to investigate the effect of food (high fat/high calorie) on the pharmacokinetics of JNJ 54175446 after single oral dose administration.

Detailed Description

This is a double-blind, placebo-controlled, randomized, single ascending dose study in healthy participants for JNJ-54175446. The study will consist of 3 phases: a screening phase (between 21 and 2 days prior to dose administration), a double-blind treatment phase (8 days; Part 1 and Part 3) or an open-label treatment phase (8 days; Part 2), and a follow-up examination (within 14 to 21 days after dose administration). The maximal study duration for a participant will not exceed 6 weeks. In each cohort of Part 1 (6 cohorts) and Part 3 (1 cohort), participants will be randomly assigned to receive JNJ-54175446 or matching placebo and in cohort of part 2, all participants will be assigned to JNJ-54175446 treatment. In part 1, primarily maximum tolerated dose (MTD) will be assessed, along with safety and tolerability of JNJ-54175446. In part 2, pharmacokinetics (PK) of JNJ-54175446 in cerebrospinal fluid (CSF) will be assessed. In part 3, the effect of food on the plasma PK of JNJ-54175446 in young healthy male participants will be assessed. Safety will be monitored throughout the study.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Part 1: Cohort 1

Participants will receive either JNJ-54175446 0.5 milligram (mg) or placebo on Day 1.

Group Type: EXPERIMENTAL

JNJ 54175446

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Part 1: Cohort 2

Participants will receive either JNJ-54175446 2.5 mg or placebo on Day 1.

Group Type: EXPERIMENTAL

JNJ 54175446

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Part 1: Cohort 3

Participants will receive either JNJ-54175446 10 mg or placebo on Day 1.

Group Type: EXPERIMENTAL

JNJ 54175446

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Part 1: Cohort 4

Participants will receive either JNJ-54175446 30 mg or placebo on Day 1.

Group Type: EXPERIMENTAL

JNJ 54175446

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Part 1: Cohort 5

Participants will receive either JNJ-54175446 100 mg or placebo on Day 1.

Group Type: EXPERIMENTAL

JNJ 54175446

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Part 1: Cohort 6

Participants will receive either JNJ-54175446 200 mg or placebo on Day 1.

Group Type: EXPERIMENTAL

JNJ 54175446

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Part 2: Cohort 7

Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.

Group Type: EXPERIMENTAL

JNJ 54175446

Intervention Type: DRUG

Part 3: Cohort 8

Participants will receive JNJ-54175446 on Day 1 along with high fat/high calorie breakfast. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.

Group Type: EXPERIMENTAL

JNJ 54175446

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

High fat/high Calorie Breakfast

Intervention Type: OTHER

Interventions

JNJ 54175446

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

High fat/high Calorie Breakfast

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Participants must have a body mass index (BMI) between 18 and 32 kg/m^2, inclusive (BMI = weight/height^2)
• Participants must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel[excluding liver function tests], hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator
• A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drug. In addition, their female partner should also use an appropriate method of birth control for at least the same duration

For Part 1 and 3:

• Healthy male participants between 18 and 54 years of age, inclusive

For Part 2:

• Healthy male or female participants between 55 and 75 years of age, inclusive
• Participant must be healthy on the basis of both physical and neurological examination performed at screening and at admission to the clinical unit
• Women must not be of childbearing potential (i.e., must be postmenopausal with amenorrhea for at least 12 months); permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy); or otherwise be incapable of pregnancy

Exclusion Criteria

• Participant has a history of or current liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic (including coagulation disorders), rheumatologic, psychiatric, or metabolic disturbances, any inflammatory illness or any other illness that the Investigator considers should exclude the participant
• Participant has any liver function test (including alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyltransferase [gamma-GT], alkaline phosphatase [ALP] and bilirubin) at screening exceeding the upper limit of normal
• Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening
• Participant has a history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at Screening
• Participant has a Prothrombin time [PT] >14 seconds and/or an activated partial thromboplastin time [aPTT] >35 seconds

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Janssen-Cilag International NV

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen-Cilag International NV Clinical Trial

Role: STUDY_DIRECTOR

Janssen-Cilag International NV

Locations

Merksem, , Belgium

Countries

Belgium

References

Triana-Baltzer G, Timmers M, De Boer P, Schoene M, Furey M, Bleys C, Vrancken I, Slemmon R, Ceusters M, van Nueten L, Kolb H. Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time. Compr Psychoneuroendocrinol. 2022 Jan 15;10:100116. doi: 10.1016/j.cpnec.2022.100116. eCollection 2022 May.

Reference Type: DERIVED

PMID: 35774109 (View on PubMed)

Other Identifiers

2015-000942-53

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

54175446EDI1001

Identifier Type: OTHER

Identifier Source: secondary_id

CR107482

Identifier Type: -

Identifier Source: org_study_id